Clinical Trial

Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B

Study acronym: ADAPT
Completed Phase 4
View on ClinicalTrials.gov →
Summary
Multicenter, Prospective Open-label Single Arm Trial Chronic hepatitis B male and female adults on antiviral treatment for hepatitis B, without cirrhosis who are currently HBV DNA (-) and HBeAg (-) To evaluate the safety and efficacy of stopping long-term antiviral therapy in chronic hepatitis B patients without cirrhosis who are currently HBV DNA (-) and HBeAg (-)
Protocol Amendment History 3 changes
critical Trial completed 2026-07-29
notable Trial sites reduced: 9 -> 4 locations 2026-07-29
minor Completion pushed: 2026-01-31 -> 2026-06-30 2026-07-29
Trial Details
NCT Number NCT04782375
Lead Sponsor Asan Medical Center
Conditions Hepatitis B, Chronic
Enrollment 140 participants
Start Date 2021-09-01
Primary Completion 2024-08-19 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04